249 related articles for article (PubMed ID: 28034354)
1. Recombinant Activated Factor VII (Eptacog Alfa Activated, NovoSeven®) in Patients with Rare Congenital Bleeding Disorders. A Systematic Review on its Use in Surgical Procedures.
Di Minno MND; Ambrosino P; Myasoedova V; Amato M; Ventre I; Tremoli E; Minno AD
Curr Pharm Des; 2017; 23(7):1125-1131. PubMed ID: 28034354
[TBL] [Abstract][Full Text] [Related]
2. Eptacog alfa activated: a recombinant product to treat rare congenital bleeding disorders.
Di Minno G
Blood Rev; 2015 Jun; 29 Suppl 1():S26-33. PubMed ID: 26073366
[TBL] [Abstract][Full Text] [Related]
3. Glanzmann's thrombasthenia treatment: a prospective observational registry on the use of recombinant human activated factor VII and other hemostatic agents.
Poon MC; Zotz R; Di Minno G; Abrams ZS; Knudsen JB; Laurian Y
Semin Hematol; 2006 Jan; 43(1 Suppl 1):S33-6. PubMed ID: 16427383
[TBL] [Abstract][Full Text] [Related]
4. Recombinant activated factor VII (NovoSeven) treatment of platelet-related bleeding disorders. International Registry on Recombinant Factor VIIa and Congenital Platelet Disorders Group.
Poon MC; d'Oiron R
Blood Coagul Fibrinolysis; 2000 Apr; 11 Suppl 1():S55-68. PubMed ID: 10850567
[TBL] [Abstract][Full Text] [Related]
5. The Use of Recombinant Activated Factor VII in Patients with Glanzmann's Thrombasthenia.
Poon MC
Thromb Haemost; 2021 Mar; 121(3):332-340. PubMed ID: 33124022
[TBL] [Abstract][Full Text] [Related]
6. Results of the WIRK prospective, non-interventional observational study of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors and other bleeding disorders.
Birschmann I; Klamroth R; Eichler H; Schenk J; Kirchmaier CM; Halimeh S
Haemophilia; 2013 Sep; 19(5):679-85. PubMed ID: 23647644
[TBL] [Abstract][Full Text] [Related]
7. NovoSeven (recombinant factor VIIa) for the treatment of bleeding episodes and perioperative management in patients with Glanzmann's thrombasthenia.
Franchini M; Lippi G
Expert Rev Hematol; 2014 Dec; 7(6):733-40. PubMed ID: 25387838
[TBL] [Abstract][Full Text] [Related]
8. Independent adjudicator assessments of platelet refractoriness and rFVIIa efficacy in bleeding episodes and surgeries from the multinational Glanzmann's thrombasthenia registry.
Recht M; Rajpurkar M; Chitlur M; d'Oiron R; Zotz R; Di Minno G; Cooper DL; Poon MC
Am J Hematol; 2017 Jul; 92(7):646-652. PubMed ID: 28370369
[TBL] [Abstract][Full Text] [Related]
9. New insights into the management of bleeding disorders.
Escolar G
Drug News Perspect; 2004 May; 17(4):285-8. PubMed ID: 15334177
[TBL] [Abstract][Full Text] [Related]
10. Use of recombinant activated factor VII in patients with Glanzmann's thrombasthenia: a review of the literature.
Rajpurkar M; Chitlur M; Recht M; Cooper DL
Haemophilia; 2014 Jul; 20(4):464-71. PubMed ID: 24948404
[TBL] [Abstract][Full Text] [Related]
11. Recombinant activated factor VII (rFVIIa, NovoSeven).
Agarwal MB; Patnaik M
J Assoc Physicians India; 2005 Aug; 53():717-20. PubMed ID: 16398083
[TBL] [Abstract][Full Text] [Related]
12. [Activated Factor VII - 31 years experience on clinical grounds].
Udvardy M
Orv Hetil; 2017 Jun; 158(24):923-928. PubMed ID: 28604077
[TBL] [Abstract][Full Text] [Related]
13. Intraoperative use of recombinant activated factor VII (rFVIIa).
De Gasperi A
Minerva Anestesiol; 2006 Jun; 72(6):489-94. PubMed ID: 16682921
[TBL] [Abstract][Full Text] [Related]
14. Clinical use of recombinant human activated factor VII (rFVIIa) in the prevention and treatment of bleeding episodes in patients with Glanzmann's thrombasthenia.
Poon MC
Vasc Health Risk Manag; 2007; 3(5):655-64. PubMed ID: 18078017
[TBL] [Abstract][Full Text] [Related]
15. NovoSeven as a universal haemostatic agent.
Hedner U
Blood Coagul Fibrinolysis; 2000 Apr; 11 Suppl 1():S107-11. PubMed ID: 10850574
[TBL] [Abstract][Full Text] [Related]
16. Safety update on the use of recombinant activated factor VII in approved indications.
Neufeld EJ; Négrier C; Arkhammar P; Benchikh el Fegoun S; Simonsen MD; Rosholm A; Seremetis S
Blood Rev; 2015 Jun; 29 Suppl 1():S34-41. PubMed ID: 26073367
[TBL] [Abstract][Full Text] [Related]
17. Recombinant factor VIIa (eptacog alfa): a review of its use in congenital hemophilia with inhibitors, acquired hemophilia, and other congenital bleeding disorders.
Croom KF; McCormack PL
BioDrugs; 2008; 22(2):121-36. PubMed ID: 18345709
[TBL] [Abstract][Full Text] [Related]
18. Surgery in patients with congenital factor VII deficiency - a single center study.
Szczepanik A; Wiszniewski A; Oses-Szczepanik A; Dąbrowski W; Pielaciński K; Misiak A
Pol Przegl Chir; 2018 May; 90(5):1-5. PubMed ID: 30426948
[TBL] [Abstract][Full Text] [Related]
19. Congenital factor VII deficiency: therapy with recombinant activated factor VII -- a critical appraisal.
Mariani G; Konkle BA; Ingerslev J
Haemophilia; 2006 Jan; 12(1):19-27. PubMed ID: 16409171
[TBL] [Abstract][Full Text] [Related]
20. Recombinant factor VIIa (Eptacog Alfa): a review of its use in congenital or acquired haemophilia and other congenital bleeding disorders.
Siddiqui MA; Scott LJ
Drugs; 2005; 65(8):1161-77. PubMed ID: 15907148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
